Cargando…

TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells

Chronic inflammation has been associated with several chronic diseases, such as age-related macular degeneration (AMD). The NLRP3 inflammasome is a central proinflammatory signaling complex that triggers caspase-1 activation leading to the maturation of IL-1β. We have previously shown that the inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranta-aho, Sofia, Piippo, Niina, Korhonen, Eveliina, Kaarniranta, Kai, Hytti, Maria, Kauppinen, Anu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125426/
https://www.ncbi.nlm.nih.gov/pubmed/34062977
http://dx.doi.org/10.3390/ijms22094875
_version_ 1783693498731462656
author Ranta-aho, Sofia
Piippo, Niina
Korhonen, Eveliina
Kaarniranta, Kai
Hytti, Maria
Kauppinen, Anu
author_facet Ranta-aho, Sofia
Piippo, Niina
Korhonen, Eveliina
Kaarniranta, Kai
Hytti, Maria
Kauppinen, Anu
author_sort Ranta-aho, Sofia
collection PubMed
description Chronic inflammation has been associated with several chronic diseases, such as age-related macular degeneration (AMD). The NLRP3 inflammasome is a central proinflammatory signaling complex that triggers caspase-1 activation leading to the maturation of IL-1β. We have previously shown that the inhibition of the chaperone protein, Hsp90, prevents NLRP3 activation in human retinal pigment epithelial (RPE) cells; these are cells which play a central role in the pathogenesis of AMD. In that study, we used a well-known Hsp90 inhibitor geldanamycin, but it cannot be used as a therapy due to its adverse effects, including ocular toxicity. Here, we have tested the effects of a novel Hsp90 inhibitor, TAS-116, on NLRP3 activation using geldanamycin as a reference compound. Using our existing protocol, inflammasome activation was induced in IL-1α-primed ARPE-19 cells with the proteasome and autophagy inhibitors MG-132 and bafilomycin A1, respectively. Intracellular caspase-1 activity was determined using a commercial caspase-1 activity kit and the FLICA assay. The levels of IL-1β were measured from cell culture medium samples by ELISA. Cell viability was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test and lactate dehydrogenase (LDH) measurements. Our findings show that TAS-116 could prevent the activation of caspase-1, subsequently reducing the release of mature IL-1β. TAS-116 has a better in vitro therapeutic index than geldanamycin. In summary, TAS-116 appears to be a well-tolerated Hsp90 inhibitor, with the capability to prevent the activation of the NLRP3 inflammasome in human RPE cells.
format Online
Article
Text
id pubmed-8125426
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81254262021-05-17 TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells Ranta-aho, Sofia Piippo, Niina Korhonen, Eveliina Kaarniranta, Kai Hytti, Maria Kauppinen, Anu Int J Mol Sci Article Chronic inflammation has been associated with several chronic diseases, such as age-related macular degeneration (AMD). The NLRP3 inflammasome is a central proinflammatory signaling complex that triggers caspase-1 activation leading to the maturation of IL-1β. We have previously shown that the inhibition of the chaperone protein, Hsp90, prevents NLRP3 activation in human retinal pigment epithelial (RPE) cells; these are cells which play a central role in the pathogenesis of AMD. In that study, we used a well-known Hsp90 inhibitor geldanamycin, but it cannot be used as a therapy due to its adverse effects, including ocular toxicity. Here, we have tested the effects of a novel Hsp90 inhibitor, TAS-116, on NLRP3 activation using geldanamycin as a reference compound. Using our existing protocol, inflammasome activation was induced in IL-1α-primed ARPE-19 cells with the proteasome and autophagy inhibitors MG-132 and bafilomycin A1, respectively. Intracellular caspase-1 activity was determined using a commercial caspase-1 activity kit and the FLICA assay. The levels of IL-1β were measured from cell culture medium samples by ELISA. Cell viability was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test and lactate dehydrogenase (LDH) measurements. Our findings show that TAS-116 could prevent the activation of caspase-1, subsequently reducing the release of mature IL-1β. TAS-116 has a better in vitro therapeutic index than geldanamycin. In summary, TAS-116 appears to be a well-tolerated Hsp90 inhibitor, with the capability to prevent the activation of the NLRP3 inflammasome in human RPE cells. MDPI 2021-05-05 /pmc/articles/PMC8125426/ /pubmed/34062977 http://dx.doi.org/10.3390/ijms22094875 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ranta-aho, Sofia
Piippo, Niina
Korhonen, Eveliina
Kaarniranta, Kai
Hytti, Maria
Kauppinen, Anu
TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title_full TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title_fullStr TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title_full_unstemmed TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title_short TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
title_sort tas-116, a well-tolerated hsp90 inhibitor, prevents the activation of the nlrp3 inflammasome in human retinal pigment epithelial cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125426/
https://www.ncbi.nlm.nih.gov/pubmed/34062977
http://dx.doi.org/10.3390/ijms22094875
work_keys_str_mv AT rantaahosofia tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells
AT piipponiina tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells
AT korhoneneveliina tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells
AT kaarnirantakai tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells
AT hyttimaria tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells
AT kauppinenanu tas116awelltoleratedhsp90inhibitorpreventstheactivationofthenlrp3inflammasomeinhumanretinalpigmentepithelialcells